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Purpose of the study
Tipranavir (TPV) is a ritonavir-boosted HIV protease
inhibitor (PI) indicated for use in treatment-experienced
patients (TEP) with PI resistance. TPV has shown superior
virologic and immunologic responses in TEPs compared
with first-generation PIs. In the Utilization of HIV Drug
Resistance in Treatment-Experienced Patients (UTILIZE)
study, we assessed the presence of susceptibility to TPV
among HIV-1 isolates in TEPs.
Methods
UTILIZE was conducted at 40 US sites and examined cli-
nician use of HIV drug-resistance testing in TEPs failing a
PI-based regimen. In this observational study, patients
were randomized to have either a genotype (GT; Mono-
gram GeneSeq) or combined phenotype-genotype test
(PGT; Monogram Phenosense GT) to assist with treat-
ment decision-making. Resistance data were evaluated to
assess TPV susceptibility among isolates from patients fail-
ing a PI-based regimen.
Summary of results
246 patients enrolled and 236 had resistance testing.
Median HIV-RNA and CD4 count were 30,538 copies/mL
and 197 cells/mm3 with no significant differences
between GT and PGT groups. There were 139 and 69
patients who had GT or PT evidence of reduced suscepti-
bility to at least one PI, respectively. Table 1 shows the per-
centage of isolates from these patients (both overall and
by number of prior PIs) demonstrating genotypic and
phenotypic susceptibility to TPV.
Conclusion
In this cohort of TEPs failing a PI-based regimen, a major-
ity of patient isolates showed full or partial susceptibility
to TPV. Even in the most PI-experienced patients, one-
third to one-half had virus that remained fully or partially
susceptible to TPV. An advantage of phenotypic testing is
that it reports both full and partial drug susceptibility
which may help guide clinician choice of TPV. When con-
structing a new regimen in PI-experienced patients, resist-
ance testing should guide the use of TPV as a potential
therapeutic option.
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Genotypic TPV susceptibility* (n = 139) Phenotypic TPV susceptibility** (n = 69)
Overall 58% 79%
1–2 previous PIs 83% 90%
3–4 previous PIs 60% 71%
5+ previous PIs 36% 52%
*includes only full susceptibility
**includes full and partial susceptibilityPage 2 of 2
(page number not for citation purposes)
